# US 2021/0268091 A1 · Neoantigens and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0268091 A1
- Document ID: US20210268091A1
- Status: Published application
- Kind: A1
- Application number: 17/254,128
- Filed: 2019-06-19
- Published: 2021-09-02
- Earliest claimed: 2018-06-19
- Assignees: Biontech US Inc.
- Applicants: BioNTech US Inc.
- Inventors: Vikram Juneja
- Web page: https://patentgrep.com/patent/US20210268091A1

## CPC

- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 39/001164: {GTPases, e.g. Ras or Rho}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4201: {Neoantigens}
- A61K 40/4253: {GTPases, e.g. Ras or Rho}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/04: specific for metastasis
- C07K 14/62: Insulins
- C07K 14/82: Translation products from oncogenes
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- A61K 2039/645: {Dendrimers; Multiple antigen peptides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.

## Claims

### Claim 1

A composition comprising:
(a) at least one polypeptide or a pharmaceutically acceptable salt thereof comprising two or more mutant RAS peptide sequences selected from the group consisting of;
(i) KLVVVGADGV, KLVVVGACGV, KLVVVGAVGV, LVVVGADGV, LVVVGACGV, LVVVGAVGV;
(ii) GADGVGKSAL, GACGVGKSAL, GAVGVGKSAL, GADGVGKSA, GACGVGKSA, GAVGVGKSA; and/or
(iii) VVGADGVGK, VVGACGVGK, VVGAVGVGK, VVVGADGVGK, VVVGACGVGK, VVVGAVGVGK; or
(b) at least one polynucleotide encoding the at least one polypeptide.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition comprises a mixture of the three or more mutant RAS peptide sequences.

### Claim 3

A composition comprising:
(a) at least one polypeptide or a pharmaceutically acceptable salt thereof comprising two or more mutant RAS peptide sequences each comprising:
(i) at least 8 contiguous amino acids of a mutant RAS protein comprising a mutation at G12, and
(ii) the mutation at G12; and
further wherein three or more amino acid residues that are heterologous to the mutant RAS protein are linked to the N-terminus or C-terminus of the two or more mutant RAS peptide sequences, wherein the three or more amino acid residues enhance processing of the mutant RAS peptide sequences in cell and/or enhance presentation of an epitope of the mutant RAS peptide sequences; or
(b) at least one polynucleotide encoding the at least one polypeptide.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the three or more amino acid residues that are heterologous to the mutant RAS protein are linked to the N-terminus or C-terminus of the two or more mutant RAS peptide sequences comprises an amino acid sequence of a protein of CMV such as pp65, HIV, or MART-1.

### Claim 5 (depends on 3, 4)

The composition of claim 3 or 4, wherein the three or more amino acid residues that are heterologous to the mutant RAS protein are linked to the N-terminus or C-terminus of the two or more mutant RAS peptide sequences comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 amino acids.

### Claim 6 (depends on 3, 4, 5)

The composition of any one of claims 3-5, wherein the three or more amino acid residues that are heterologous to the mutant RAS protein are linked to the N-terminus or C-terminus of the two or more mutant RAS peptide sequences comprises at most 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 50, 60, 70, 80, 90, or 100 amino acids.

### Claim 7

A composition comprising
(a) at least one polypeptide or a pharmaceutically acceptable salt thereof of the formula (XaaN)N-(XaaRAS)P-(XaaC)C
wherein
P is an integer greater than 7;
(XaaRAS)P is a mutant RAS peptide sequence comprising at least 8 contiguous amino acids of a mutant RAS protein; the at least 8 contiguous amino acids comprising at least 8 contiguous amino acids of the sequence
Lys1 Leu2 Val3 Val4 Val5 Gly6 Ala7 Xaa8 Gly9 Val10 Gly11 Lys12 Ser13 Ala14Leu15
N is (i) 0 or (ii) an integer greater than 2;
(XaaN)N is any amino acid sequence heterologous to the mutant RAS protein;
C is (i) 0 or (ii) an integer greater than 2;
(XaaC)C is any amino acid sequence heterologous to the mutant RAS protein;
Xaa8 is selected from the group consisting of Asp, Val, Cys, Ala, Arg and Ser;
the polypeptide is not KLVVVGAVGVGKSALTIQL; and
wherein if N is 0 C is not 0 and if C is 0 N is not 0; or
(b) at least one polynucleotide encoding the at least one polypeptide.

### Claim 8 (depends on 7)

The composition of claim 7, wherein (Xaa)N and/or (XaaC)C comprises an amino acid sequence of a protein of CMV such as pp65, HIV, or MART-1.

### Claim 9 (depends on 7, 8)

The composition of claim 7 or 8, wherein N and/or C is an integer greater than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40.

### Claim 10 (depends on 7, 8, 9)

The composition of any one of claims 7-9, wherein N and/or C is an integer less than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 50, 60, 70, 80, 90, or 100.

### Claim 11 (depends on 7, 8, 9, 10)

The composition of any one of claims 7-10, wherein N is O.

### Claim 12 (depends on 7, 8, 9, 10)

The composition of any one of claims 7-10, wherein C is 0.

### Claim 13

A composition comprising
(a) at least one polypeptide or a pharmaceutically acceptable salt thereof comprising of an amino acid sequence of
Xaa1-Xaa2-Val3-Val4-Val5-Gly6-Ala7-Xaa8-Gly9-Xaa10
wherein
Xaa1 is not Ala;
with the proviso that when Xaa1 is not Lys, Xaa2 is Leu and/or Xaa10 is Gly;
Xaa2 is not Glu;
with the proviso that when Xaa2 is not Leu, Xaa1 is Lys and/or Xaa10 is Gly;
Xaa8 is selected from the group consisting of Asp, Val, Cys, Ala, Arg and Ser;
with the proviso that when Xaa8 is Glu, Xaa1 is not Tyr and/or Xaa2 is not Leu, and
with the proviso that when Xaa8 is Val, Xaa1 is not Lys;
Xaa10 is any amino acid;
with the proviso that when Xaa10 is not Gly, Xaa1 is Lys and/or Xaa2 is Leu; and
the polypeptide comprises an HLA-A02:01-restricted T cell epitope, HLA-A03:01-restricted T cell epitope, an HLA-A11:01-restricted T cell epitope, an HLA-A03:02-restricted T cell epitope, an HLA-A30:01-restricted T cell epitope, an HLA-A31:01-restricted T cell epitope, an HLA-A33:01-restricted T cell epitope, an HLA-A33:03-restricted T cell epitope, an HLA-A68:01-restricted T cell epitope, or an HLA-A74:01-restricted T cell epitope that binds to an HLA-A02:01, HLA-A03:01, HLA-A11:01, HLA-A03:02, HLA-A30:01, HLA-A31:01, HLA-A33:01, HLA-A33:03, HLA-A68:01, and/or an HLA-A74:01 molecule; and
induces an HLA-A02:01-restricted cytotoxic T cell response, an HLA-A02:01-restricted cytotoxic T cell response, HLA-A03:01-restricted cytotoxic T cell response, an HLA-A11:01-restricted cytotoxic T cell response, an HLA-A03:02-restricted cytotoxic T cell response, an HLA-A30:01-restricted cytotoxic T cell response, an HLA-A31:01-restricted cytotoxic T cell response, an HLA-A33:01-restricted cytotoxic T cell response, an HLA-A33:03-restricted cytotoxic T cell response, an HLA-A68:01-restricted cytotoxic T cell response, or an HLA-A74:01-restricted cytotoxic T cell response; and
that binds to an HLA-A02:01, HLA-A03:01, HLA-A11:01, HLA-A03:02, HLA-A30:01, HLA-A31:01, HLA-A33:01, HLA-A33:03, HLA-A68:01, and/or an HLA-A74:01; or
(b) at least one polynucleotide encoding the at least one polypeptide.

### Claim 14

A composition comprising:
(a) at least one polypeptide or a pharmaceutically acceptable salt thereof comprising one or more mutant RAS peptide sequences each comprising:
(i) at least 8 contiguous amino acids of a mutant RAS protein comprising a G12A, G12C, G12D, G12R, G12S, or G12V mutation, and
(ii) the G12A, G12C, G12D, G12R, G12S, or G12V mutation; and
further wherein the peptide:
(i) comprises a mutation not encoded by a genome of a cancer cell and has an affinity or predicted affinity of 150 nM or less for an HLA-A02:01 allele and/or a half-life of 2 hours or more, or
(j) has a half life of 2 hours or more and an affinity or predicted affinity of 150 nM or less for an HLA-A02:01 allele, an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, or an HLA-A74:01 allele and/or an HLA-008:02 allele; or
(b) at least one polynucleotide encoding the at least one polypeptide.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The composition of any one of claims 1 to 14, wherein the composition further comprises (i) a peptide comprising a peptide sequence in any one of Table 3 to 14, or (ii) a polynucleotide encoding the peptide comprising a sequence in Table 3 to 14.

### Claim 16

A composition comprising:
(a) at least one polypeptide or a pharmaceutically acceptable salt thereof comprising one or more mutant RAS peptide sequences selected from the group consisting of: DTAGHEEY, TAGHEEYSAM, DILDTAGHE, DILDTAGH, ILDTAGHEE, ILDTAGHE, DILDTAGHEEY, DTAGHEEYS, LLDILDTAGH, DILDTAGRE, DILDTAGR, ILDTAGREE, ILDTAGRE, CLLDILDTAGR, TAGREEYSAM, REEYSAMRD, DTAGKEEYSAM, CLLDILDTAGK, DTAGKEEY, LLDILDTAGK, ILDTAGKE, ILDTAGKEE, DTAGLEEY, ILDTAGLE, DILDTAGL, ILDTAGLEE, GLEEYSAMRDQY, LLDILDTAGLE, LDILDTAGL, DILDTAGLE, DILDTAGLEEY, AGVGKSAL, GAAGVGKSAL, AAGVGKSAL, CGVGKSAL, ACGVGKSAL, DGVGKSAL, ADGVGKSAL, DGVGKSALTI, GARGVGKSA, KLVVVGARGV, VVVGARGV, SGVGKSAL, VVVGASGVGK, GASGVGKSAL, VGVGKSAL, VVVGAGCVGK, KLVVVGAGC, GDVGKSAL, DVGKSALTI, VVVGAGDVGK, TAGKEEYSAM, DTAGHEEYSAM, TAGHEEYSA, DTAGREEYSAM, TAGKEEYSA, AAGVGKSA, AGCVGKSAL, AGDVGKSAL, AGKEEYSAMR, AGVGKSALTI, ARGVGKSAL, ASGVGKSA, ASGVGKSAL, AVGVGKSA, CVGKSALTI, DILDTAGK, DILDTAGREEY, DTAGHEEYSAMR, DTAGKEEYS, DTAGKEEYSAMR, DTAGLEEYS, DTAGLEEYSA, DTAGLEEYSAMR, DTAGREEYS, DTAGREEYSAMR, GAAGVGKSA, GACGVGKSA, GACGVGKSAL, GADGVGKS, GAGDVGKSA, GAGDVGKSAL, GASGVGKSA, GCVGKSAL, GCVGKSALTI, GHEEYSAM, GKEEYSAM, GLEEYSAMR, GREEYSAM, GREEYSAMR, HEEYSAMRD, KEEYSAMRD, KLVVVGASG, LDILDTAGR, LEEYSAMRD, LVVVGARGV, LVVVGASGV, REEYSAMRDQY, RGVGKSAL, TAGLEEYSA, TEYKLVVVGAA, VGAAGVGKSA, VGADGVGK, VGASGVGKSA, VGVGKSALTI, VVVGAAGV, VVVGAVGV, YKLVVVGAC, YKLVVVGAD, YKLVVVGAR, and DILDTAGKE; or
(b) at least one polynucleotide encoding the at least one polypeptide.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the composition further comprises;
(i) a peptide comprising a peptide sequence in any one of Tables 1 to 14, or
(ii) a polynucleotide encoding the peptide comprising a sequence in Tables 1 to 14.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The composition of any one of claims 1-17, wherein at least one of the mutant RAS peptide sequences comprises N or C terminal amino acid sequence extension of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 amino acids, wherein the N or C terminal extension is a wild-type RAS amino acid sequence or a non-heterologous RAS amino acid sequence.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The composition of any one of claims 1-18, wherein the at least one polypeptide comprises at least 3, 4, 5, 6, 7, 8, 9, or 10 mutant RAS peptide sequences.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein the at least one polypeptide comprises at least two polypeptides, or the at least one polynucleotide comprises at least two polynucleotides.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 1-20, wherein at least one of the mutant RAS peptide sequences comprises at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous amino acids of a mutant RAS protein.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The composition of any one of claims 1-21, wherein at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the mutant RAS peptide sequences comprise at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous amino acids of a mutant RAS protein.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The composition of any one of claims 1-22, wherein each of the mutant RAS peptide sequences or each of the two or more RAS peptide sequences comprises at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous amino acids of a mutant RAS protein.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The composition of any one of claims 1-23, wherein the at least one polypeptide comprises at least one mutant RAS peptide sequence that binds to or is predicted to bind to a protein encoded by an HLA-A02:01 allele, an HLA-A03:01 allele, an HLA-A11:01 allele, and/or an HLA-008:02 allele.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 1-24, wherein the at least one polypeptide comprises at least one mutant RAS peptide sequence that binds to or is predicted to bind to a protein encoded by:
(a) an HLA-A02:01 allele and an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, or an HLA-A74:01 allele;
(b) an HLA-A02:01 allele and an HLA-008:02 allele;
(c) an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, or an HLA-A74:01 allele and an HLA-008:02 allele; or
(d) an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, or an HLA-A74:01 allele and allele and an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, or an HLA-A74:01 allele.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The composition of any one of claims 1-25, wherein the mutant RAS peptide sequences comprise;
(a) a first mutant RAS peptide sequence that binds to or is predicted to bind to a protein encoded by an HLA-A02:01 allele, an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, an HLA-A74:01 allele, and/or an HLA-008:02 allele; and
(b) a second RAS peptide sequence that binds to or is predicted to bind to a protein encoded by an HLA-A02:01 allele, an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, an HLA-A74:01 allele, and/or an HLA-008:02 allele;
wherein, the first mutant RAS peptide sequence binds to or is predicted to bind to a protein encoded by different HLA allele than the second mutant RAS peptide sequence.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The composition of any one of claims 1-26, wherein the at least one polypeptide comprises at least one mutant RAS peptide sequence that binds to a protein encoded by an HLA allele with an affinity of less than 10 μM, less than 1 μM, less than 500 nM, less than 400 nM, less than 300 nM, less than 250 nM, less than 200 nM, less than 150 nM, less than 100 nM, or less than 50 nM.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The composition of any one of claims 1-27, wherein the at least one polypeptide comprises at least one mutant RAS peptide sequence that binds to a protein encoded by an HLA allele with a stability of greater than 24 hours, greater than 12 hours, greater than 9 hours, greater than 6 hours, greater than 5 hours, greater than 4 hours, greater than 3 hours, greater than 2 hours, greater than 1 hour, greater than 45 minutes, greater than 30 minutes, greater than 15 minutes, or greater than 10 minutes.

### Claim 29 (depends on 27, 28)

The composition of claim 27 or 28, wherein the HLA allele is selected from the group consisting of HLA-A02:01 allele, an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, an HLA-A74:01 allele, and/or an HLA-008:02 allele and any combination thereof.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The composition of any one of claims 1-29, wherein the at least one polypeptide comprises at least one of the following sequences: LVVVGACGV, KLVVVGACGV, LVVVGADGV, KLVVVGADGV, LVVVGAVGV, KLVVVGAVGV, VVGACGVGK, VVVGACGVGK, VVGADGVGK, VVVGADGVGK, VVGAVGVGK, VVVGAVGVGK, VVGACGVGK, VVGADGVGK, VVVGADGVGK, VVGAVGVGK, and VVVGAVGVGK.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The composition of any one of claims 1-30, wherein the mutant RAS peptide sequences comprise at least one or two of the following sequences: KLVVVGACGV, FLVVVGACGL, FMVVVGACGI, FLVVVGACGI, FMVVVGACGV, FLVVVGACGV, MLVVVGACGV, FMVVVGACGL, YLVVVGACGV, KMVVVGACGV, YMVVVGACGV, and MMVVVGACGV.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The composition of any one of claims 1-31, wherein the mutant RAS peptide sequences comprise at least one or two of the following sequences:
(a) TEYKLVVVGAVGV;
(b) WQAGILARKLVVVGAVGVQGQNLKYQ;
(c) HSYTTAEKLVVVGAVGVILGVLLLI;
(d) PLTEEKIKKLVVVGAVGVEKEGKISK;
(e) GALHFKPGSRKLVVVGAVGVAASDFIFLVT;
(f) RRANKDATAEKLVVVGAVGVKELKQVASPF;
(g) KAFISHEEKRKLVVVGAVGVKKKLINEKKE;
(h) TDLSSRFSKSKLVVVGAVGVKKCDISLQFF;
(i) FDLGGGTFDVKLVVVGAVGVKSTAGDTHLG; or
(j) CLLLHYSVSKKLVVVGAVGVATFYVAVTVP.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The composition of any one of claims 1-32, wherein (Xaa)N comprises an amino acid sequence of IDIIMKIRNA, FFFFFFFFFFFFFFFFFFFFIIFFIFFWMC, FFFFFFFFFFFFFFFFFFFFFFFFAAFWFW, IFFIFFIIFFFFFFFFFFFFIIIIIIIWEC, FIFFFIIFFFFFIFFFFFIFIIIIIIFWEC, TEY, WQAGILAR, HSYTTAE, PLTEEKIK, GALHFKPGSR, RRANKDATAE, KAFISHEEKR, TDLSSRFSKS, FDLGGGTFDV, CLLLHYSVSK, or MTEYKLVVV.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The composition of any one of claims 1-33, wherein (XaaC)C comprises an amino acid sequence of
KKNKKDDIKD, AGNDDDDDDDDDDDDDDDDDKKDKDDDDDD,
AGNKKKKKKKNNNNNNNNNNNNNNNNNNNN,
AGRDDDDDDDDDDDDDDDDDDDDDDDDDDD, GKSALTIQL, GKSALTI,
QGQNLKYQ, ILGVLLLI, EKEGKISK, AASDFIFLVT,
KELKQVASPF, KKKLINEKKE, KKCDISLQFF, KSTAGDTHLG,
ATFYVAVTVP, LTIQLIQNHFVDEYDPTIEDSYRKQVVIDG, or
TIQLIQNHFVDEYDPTIEDSYRKQVVIDGE.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The composition of any one of claims 1-34, wherein a first mutant RAS peptide sequence comprises a first neoepitope of a mutant RAS protein and a second mutant RAS peptide sequence comprises a second neoepitope of a mutant RAS protein, wherein the first mutant RAS peptide sequence is different from the mutant RAS peptide sequence, and wherein the first neoepitope comprises at least one mutant amino acid and the second neoepitope comprises the same mutant amino acid.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The composition of any one of claims 1-35, wherein at least one of the mutant RAS peptide sequences comprises a mutant amino acid not encoded by the genome of a cancer cell of a subject.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The composition of any one of claims 1-36, wherein each of the mutant RAS peptide sequences are present at a concentration at least 1 μg/mL, at least 10 μg/mL, at least 25 μg/mL, at least 50 μg/mL, or at least 100 μg/mL.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The composition of any one of claims 1-36, wherein each of the mutant RAS peptide sequences are present at a concentration at most 5000 μg/mL, at most 2500 μg/mL, at most 1000 μg/mL, at most 750 μg/mL, at most 500 μg/mL, at most 400 μg/mL, or at most 300 μg/mL.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The composition of any one of claims 1-36, wherein each of the mutant RAS peptide sequences are present at a concentration of from 10 μg/mL to 5000 μg/mL, 10 μg/mL to 4000 μg/mL, 10 μg/mL to 3000 μg/mL, 10 μg/mL to 2000 μg/mL, 10 μg/mL to 1000 μg/mL, 25 μg/mL to 500 μg/mL, or 50 μg/mL to 300 μg/mL.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The composition of any one of claims 1-39, wherein the composition further comprises different mutant RAS peptide sequence with a G13A, G13C, G13D, G13R, G13S, G13V, G12A, G12C, G12D, G12R, G12S, G12V or a Q61 mutation.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The composition of any one of claims 1-40, wherein the composition further comprises an immunomodulatory agent or an adjuvant.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the adjuvant is polyICLC.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A pharmaceutical composition comprising:
(a) the composition of any one of claims 1-42, and
(b) a pharmaceutically acceptable excipient.

### Claim 44 (depends on 43)

The pharmaceutical composition of claim 43, wherein the pharmaceutical composition comprises a pH modifier present at a concentration of less than 1 mM or greater than 1 mM.

### Claim 45 (depends on 43, 44)

The pharmaceutical composition of claim 43 or 44, wherein the pharmaceutical composition is a vaccine composition.

### Claim 46 (depends on 43, 44, 45)

The pharmaceutical composition of any one of claims 43-45, wherein the pharmaceutical composition is aqueous.

### Claim 47 (depends on 43, 44, 45, 46)

The pharmaceutical composition of any one of claims 43-46, wherein one or more of the at least one polypeptide is bounded by
(a) pI>5 and HYDRO>−6,
(b) pI>8 and HYDRO>−8,
(c) pI<5 and HYDRO>−5,
(d) pI>9 and HYDRO<−8,
(e) pI>7 and a HYDRO value of >−5.5,
(f) pI<4.3 and −4≥HYDRO≥−8,
(g) pI>0 and HYDRO<−8, pI>0 and HYDRO>−4, or pI>4.3 and −4≥HYDRO≥−8,
(h) pI>0 and HYDRO>−4, or pI>4.3 and HYDRO≤−4,
(i) pI>0 and HYDRO>−4, or pI>4.3 and −4≥HYDRO≥−9,
(j) 5≥pI≥12 and −4≥HYDRO≥−9.

### Claim 48 (depends on 43, 44, 45, 46, 47)

The pharmaceutical composition of any one of claims 43-47, wherein the pH modifier is a base.

### Claim 49 (depends on 43, 44, 45, 46, 47, 48)

The pharmaceutical composition of any one of claims 43-48, wherein the pH modifier is a conjugate base of a weak acid.

### Claim 50 (depends on 43, 44, 45, 46, 47, 48, 49)

The pharmaceutical composition of any one of claims 43-49, wherein the pH modifier is a pharmaceutically acceptable salt.

### Claim 51 (depends on 43, 44, 45, 46, 47, 48, 49, 50)

The pharmaceutical composition of any one of claims 43-50, wherein the pH modifier is a dicarboxylate or tricarboxylate salt.

### Claim 52 (depends on 43, 44, 45, 46, 47, 48, 49, 50)

The pharmaceutical composition of any one of claims 43-50, wherein the pH modifier is citric acid and/or a citrate salt.

### Claim 53 (depends on 52)

The pharmaceutical composition of claim 52, wherein the citrate salt is disodium citrate and/or trisodium citrate.

### Claim 54 (depends on 43, 44, 45, 46, 47, 48, 49, 50)

The pharmaceutical composition of any one of claims 43-50, wherein the pH modifier is succinic acid and/or a succinate salt.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein the succinate salt is a disodium succinate and/or a monosodium succinate.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the succinate salt is disodium succinate hexahydrate.

### Claim 57 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The pharmaceutical composition of any one of claims 43-55, wherein the pH modifier is present at a concentration of from 0.1 mM-1 mM.

### Claim 58 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The pharmaceutical composition of any one of claims 43-57, wherein the pharmaceutically acceptable carrier comprises a liquid.

### Claim 59 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The pharmaceutical composition of any one of claims 43-58, wherein the pharmaceutically acceptable carrier comprises water.

### Claim 60 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The pharmaceutical composition of any one of claims 43-59, wherein the pharmaceutically acceptable carrier comprises a sugar.

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein the sugar comprises dextrose.

### Claim 62 (depends on 61)

The pharmaceutical composition of claim 61, wherein the dextrose is present at a concentration of from 1-10% w/v.

### Claim 63 (depends on 60, 61, 62)

The pharmaceutical composition of any one of claims 60-62, wherein the sugar comprises trehalose.

### Claim 64 (depends on 60, 61, 62, 63)

The pharmaceutical composition of any one of claims 60-63, wherein the sugar comprises sucrose.

### Claim 65 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The pharmaceutical composition of any one of claims 43-64, wherein the pharmaceutically acceptable carrier comprises dimethyl sulfoxide (DMSO).

### Claim 66 (depends on 65)

The pharmaceutical composition of claim 65, wherein the DMSO is present at a concentration from 0.1% to 10%, 0.5% to 5%, or 1% to 3%.

### Claim 67 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The pharmaceutical composition of any one of claims 43-64, wherein the pharmaceutically acceptable carrier does not comprise dimethyl sulfoxide (DMSO).

### Claim 68 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The pharmaceutical composition of any one of claims 43-67, wherein the pharmaceutical composition is lyophilizable.

### Claim 69 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The pharmaceutical composition of any one of claims 43-68, wherein the pharmaceutical composition further comprises an immunomodulator or adjuvant.

### Claim 70 (depends on 69)

The pharmaceutical composition of claim 69, wherein the immunomodulator or adjuvant is selected from the group consisting of poly-ICLC, 1018 ISS, aluminum salts, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, ARNAX, STING agonists, dSLIM, GM-CSF, FLT-3L, IC30, IC31, Imiquimod, ImuFact IMP321, IS Patch, ISS, ISCOMATRIX, Juvlmmune, LipoVac, MF59, monophosphoryllipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, PepTel®, vector system, PLGA microparticles, resiquimod, SRL172, Virosomes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, and Aquila's QS21 stimulon.

### Claim 71 (depends on 69, 70)

The pharmaceutical composition of claim 69 or 70, wherein the immunomodulator or adjuvant comprises poly-ICLC.

### Claim 72 (depends on 71)

The pharmaceutical composition of claim 71, wherein a ratio of poly-ICLC to peptides in the pharmaceutical composition is from 2:1 to 1:10 v:v.

### Claim 73 (depends on 72)

The pharmaceutical composition of claim 72, wherein the ratio of poly-ICLC to peptides in the pharmaceutical composition is about 1:1, 1:2, 1:3, 1:4 or 1:5 v:v.

### Claim 74 (depends on 73)

The pharmaceutical composition of claim 73, wherein the ratio of poly-ICLC to peptides in the pharmaceutical composition is about 1:3 v:v.

### Claim 75 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

A method of treating a subject with cancer comprising administering to the subject the pharmaceutical composition of any one of claims 43-74.

### Claim 76

A method of treating a subject with cancer comprising administering to the subject a peptide with a sequence of VVGADGVGK, VVGACGVGK, VVGAVGVGK, VVVGADGVGK, VVVGACGVGK, VVVGAVGVGK, wherein the subject expresses a protein encoded by an HLA-A02:01 allele, an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, an HLA-A74:01 allele, or an HLA-008:02 allele of the subject's genome.

### Claim 77

A method of treating a subject with cancer comprising administering to the subject a mutant RAS peptide or a nucleic acid encoding the mutant RAS peptide, wherein the mutant RAS peptide comprises at least 8 contiguous amino acids of a mutant RAS protein comprising a mutation at G12, wherein the peptide comprises the mutation at G12 and binds to HLA-A11:01 or HLA-A03:01, wherein the subject is identified as expressing a protein encoded by an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, or an HLA-A74:01 allele.

### Claim 78

A method of treating a subject with cancer comprising administering to the subject a peptide comprising a sequence GADGVGKSAL, GACGVGKSAL, GAVGVGKSAL, GADGVGKSA, GACGVGKSA, or GAVGVGKSA; wherein the subject expresses a protein encoded by an HLA-A02:01 allele, an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, an HLA-A74:01 allele, or an HLA-008:02 allele of the subject's genome that binds to the peptide.

### Claim 79

A method of treating a subject with cancer comprising administering to the subject a first and a second peptide or a nucleic acid encoding the first and second peptide, wherein the first and second peptides comprise at least two of: (1) KLVVVGADGV, KLVVVGACGV, KLVVVGAVGV, LVVVGADGV, LVVVGACGV, LVVVGAVGV; (2) GADGVGKSAL, GACGVGKSAL, GAVGVGKSAL, GADGVGKSA, GACGVGKSA, GAVGVGKSA; and (3) VVGADGVGK, VVGACGVGK, VVGAVGVGK, VVVGADGVGK, VVVGACGVGK, VVVGAVGVGK; wherein the subject's HLA allele expression is unknown at the time of administration.

### Claim 80

A method of treating a subject with cancer comprising administering to the subject a mutant RAS peptide or a nucleic acid encoding the mutant RAS peptide, wherein the mutant RAS peptide comprises at least 8 contiguous amino acids of a mutant RAS protein comprising a G12C mutation, wherein the peptide comprises the G12C mutation, and further wherein the peptide comprises a stabilizing mutation not encoded by a genome of a cancer cell, wherein the subject expresses a protein encoded by an HLA-A02:01 allele, an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, an HLA-A74:01 allele, or an HLA-008:02 allele.

### Claim 81

A method of identifying a subject with cancer as a candidate for a therapeutic, the method comprising identifying the subject as a subject that expresses a protein encoded by an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, or an HLA-A74:01 allele, wherein the therapeutic is a mutant RAS peptide or a nucleic acid encoding the mutant RAS peptide, wherein the mutant RAS peptide comprises at least 8 contiguous amino acids of a mutant RAS protein comprising a mutation at G12, wherein the peptide comprises the mutation at G12 and binds to a protein encoded by an HLA-A03:01 allele, an HLA-A11:01 allele, an HLA-A03:02 allele, an HLA-A30:01 allele, an HLA-A31:01 allele, an HLA-A33:01 allele, an HLA-A33:03 allele, an HLA-A68:01 allele, or an HLA-A74:01 allele.

### Claim 82 (depends on 81)

The method of claim 81, wherein the method further comprises administering the therapeutic to the subject.

### Claim 83

A method of treating a subject with cancer, the method comprising:
(a) identifying a first protein expressed by the subject, wherein the first protein is encoded by a first HLA allele of the subject and wherein the first HLA allele is an HLA allele provided in any one of Tables 1 to 14; and
(b) administering to the subject (i) a first mutant RAS peptide, wherein the first mutant RAS peptide is a peptide to the first HLA allele provided in any one of Tables 1 to 14, or (ii) a polynucleic acid encoding the first mutant RAS peptide.

### Claim 84 (depends on 83)

The method of claim 83, further comprising identifying a second protein expressed by the subject, wherein the second protein is encoded by a second HLA allele of the subject and wherein the second HLA allele is an HLA allele provided in any one of Tables 1 to 14.

### Claim 85 (depends on 84)

The method of claim 84, further comprising administering to the subject (i) a second mutant RAS peptide, wherein the second mutant RAS peptide is a peptide to the second HLA allele provided in any one of Tables 1 to 14, or (ii) a polynucleic acid encoding the second mutant RAS peptide.

### Claim 86 (depends on 84, 85)

The method of claim 84 or 85, wherein the first HLA allele is different from the second HLA allele.

### Claim 87 (depends on 84, 85)

The method of claim 84 or 85, wherein the first mutant RAS peptide is different from the second mutant RAS peptide.

### Claim 88 (depends on 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method of any one of claims 75-87, wherein an immune response is elicited in the subject.

### Claim 89 (depends on 88)

The method of claim 88, wherein the immune response is a humoral response.

### Claim 90 (depends on 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 75-89, wherein the mutant RAS peptide sequences are administered simultaneously, separately or sequentially.

### Claim 91 (depends on 90)

The method of claim 90, wherein the first peptide is sequentially administered after a time period sufficient for the second peptide to activate the second T cells.

### Claim 92 (depends on 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The method of any one of claims 75-91, wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, uterine cancer and liver cancer.

### Claim 93 (depends on 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 75-92, further comprising administering at least one additional therapeutic agent or modality.

### Claim 94 (depends on 93)

The method of claim 93, wherein the at least one additional therapeutic agent or modality is surgery, a checkpoint inhibitor, an antibody or fragment thereof, a chemotherapeutic agent, radiation, a vaccine, a small molecule, a T cell, a vector, and APC, a polynucleotide, an oncolytic virus or any combination thereof.

### Claim 95 (depends on 94)

The method of claim 94, wherein the at least one additional therapeutic agent is an anti-PD-1 agent and anti-PD-L1 agent, an anti-CTLA-4 agent, or an anti-CD40 agent.

### Claim 96 (depends on 94, 95)

The method of claim 94 or 95, wherein the additional therapeutic agent is administered before, simultaneously, or after administering the mutant RAS peptide sequences.
